Charles River Laboratories (CRL) Misses Q3 EPS by 1c; Tightens FY11 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $345.37 +1.68%
Revenue Growth %: -4.0%
Financial Fact:
Operating income: 58.8M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -4.0%
Financial Fact:
Operating income: 58.8M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Charles River Laboratories Int'l (NYSE: CRL) reported Q3 EPS of $0.57, $0.01 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $277.6 million versus the consensus estimate of $280.45 million.
Charles River Laboratories sees FY2011 EPS of $2.40-$2.45, versus prior guidance of $2.38-$2.48 and the consensus of $2.45.
Charles River Laboratories sees FY2011 EPS of $2.40-$2.45, versus prior guidance of $2.38-$2.48 and the consensus of $2.45.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- World Acceptance (WRLD) Tops Q2 EPS by 113c
- First Hawaiian (FHB) Misses Q3 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
